trending Market Intelligence /marketintelligence/en/news-insights/trending/PpyBaDbOTUov0kH_1sRlaw2 content esgSubNav
In This List

Mylan recalls 2 batches of cancer-related injection

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Mylan recalls 2 batches of cancer-related injection

Pennsylvania-based generic-drug maker Mylan NV has voluntarily recalled two U.S.-distributed batches of its Levoleucovorin injection due to copper salt particles found in the drug.

The recall, initiated as a result of annual stability testing, is being conducted through the company's Illinois subsidiary Mylan Institutional Inc.

Levoleucovorin injection is used to treat toxicity associated with cancer drugs such as methotrexate and chemotherapy. The batches of 250-milligram ingredient in 25 mL vials were distributed in the U.S. between August 2017 and July 2018, according to Mylan.

No adverse events have been reported as a result of the contamination, but the presence of particulates could lead to problems such as irritation, allergic reactions and more.

The company urged wholesalers, retailers and consumers to examine their stock of the drug for the batches.

Another of Mylan's drugs, the blood pressure drug valsartan, has been among the subjects of another recall since July 2018 due to the presence of possible carcinogens in one of its ingredients originating in China.